Ionis Pharmaceuticals IONS EPS (Basic)
EPS (Basic) at other companies
Other financials
Where this comes from
Reported directly by Ionis Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:EarningsPerShareBasic.
The official record: Ionis Pharmaceuticals’s 10-Q, filed April 29, 2026, on SEC EDGAR. View the filing →
Ask your AI about Ionis Pharmaceuticals's eps (basic).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Ionis Pharmaceuticals's EPS (basic)?
- Ionis Pharmaceuticals (IONS) reported EPS (basic) of -$0.56 in Q1 2026.
- How has Ionis Pharmaceuticals's EPS (basic) changed year-over-year?
- Ionis Pharmaceuticals's EPS (basic) increased by 39.8% year-over-year, from -$0.93 to -$0.56.
- What is the long-term trend for Ionis Pharmaceuticals's EPS (basic)?
- Over 4 years (2021 to 2025), Ionis Pharmaceuticals's EPS (basic) has grown at a 85.3% compound annual growth rate (CAGR), from -$0.20 to -$2.36.
- What does EPS (basic) mean?
- Profit per share based on the actual number of shares currently outstanding.
- How do you interpret EPS (basic)?
- Higher basic EPS indicates better profitability for existing shareholders without accounting for future dilution.
- How does EPS (basic) compare across companies?
- Standard metric for evaluating current earnings power per share.